α受体阻滞剂与良性前列腺增生患者痴呆风险:基于国民健康保险服务数据库的全国性人群研究
该研究利用韩国国民健康保险服务数据库,纳入2011年1月至12月全国成年良性前列腺增生患者59,263例,随访至2017年9月,采用倾向评分匹配的Cox比例风险回归和Kaplan-Meier生存分析评估α受体阻滞剂与痴呆风险的关系。结果显示,坦索罗辛组与多沙唑嗪组、阿夫唑嗪组的痴呆风险无显著差异,特拉唑嗪组痴呆风险高于坦索罗辛组,但显著低于未用药组。结论认为良性前列腺增生药物与痴呆风险无关,无论用药时长或药物类型。
要点
- 倾向评分匹配后,坦索罗辛组与多沙唑嗪组痴呆风险无显著差异(HR 1.038,95%CI 0.960-1.121)。
- 坦索罗辛组与阿夫唑嗪组痴呆风险无显著差异(HR 1.008,95%CI 0.925-1.098)。
- 特拉唑嗪组痴呆风险高于坦索罗辛组(HR 1.112,95%CI 1.052-1.196),但显著低于未用药组。
核心结论
- 研究结果表明,良性前列腺增生药物与痴呆风险无关,无论用药时长或药物类型。
研究设计与样本
- 基于韩国国民健康保险服务数据库的全国性人群研究,纳入2011年1月至12月韩国成年良性前列腺增生患者,随访至2017年9月。
- 共纳入符合所有入选和排除标准的良性前列腺增生患者59,263例,平均随访1,580±674.3天。
- 采用倾向评分匹配的Cox比例风险回归模型和Kaplan-Meier生存分析评估α受体阻滞剂对痴呆风险的影响。
主要发现
- 未调整队列中,坦索罗辛组、多沙唑嗪组、特拉唑嗪组、阿夫唑嗪组和未用药组的痴呆发生率分别为17.97%、18.55%、20.64%、17.62%和22.60%。
- 倾向评分匹配后,坦索罗辛组与多沙唑嗪组痴呆风险无显著差异(HR 1.038,95%CI 0.960-1.121)。
- 倾向评分匹配后,坦索罗辛组与阿夫唑嗪组痴呆风险无显著差异(HR 1.008,95%CI 0.925-1.098)。
- 与坦索罗辛组相比,特拉唑嗪组痴呆风险较高(HR 1.112,95%CI 1.052-1.196)。
- 特拉唑嗪组痴呆风险显著低于未用药组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A recent study demonstrated that tamsulosin increased the risk of dementia in patients with benign prostatic hyperplasia. However, this study had a number of limitations. We evaluated the association between α-blockers and dementia in patients with benign prostatic hyperplasia. MATERIALS AND METHODS: From the National Health Insurance Service database we collected and analyzed data on α-blockers and dementia in the entire Korean adult population with benign prostatic hyperplasia between January 2011 and December 2011. These patients were followed until September 2017. We tested the effect of α-blockers on the risk of dementia using propensity score matched Cox proportional hazard regression models and Kaplan-Meier survival analysis. RESULTS: During a mean ± SD followup of 1,580 ± 674.3 days all study inclusion and exclusion criteria were met by 59,263 patients with benign prostatic hyperplasia. In the unadjusted cohort the incidence of dementia in the tamsulosin, doxazosin, terazosin, alfuzosin and no medication cohorts were 17.97%, 18.55%, 20.64%, 17.62% and 22.60%, respectively. After propensity score matching the risk of dementia did not significantly differ in the tamsulosin cohort vs the doxazosin and alfuzosin cohorts (HR 1.038, 95% CI 0.960-1.121 and HR 1.008, 95% CI 0.925-1.098), respectively. Compared to the tamsulosin cohort the terazosin cohort had a higher risk of dementia (HR 1.112, 95% CI 1.052-1.196). However, the risk of dementia was significantly lower in the terazosin cohort than in the no medication cohort. CONCLUSIONS: The study findings indicate that benign prostatic hyperplasia medication is not associated with a risk of dementia by duration of use or by type.
引用
- Tae BS, Jeon BJ, Choi H, et al. α-Blocker and Risk of Dementia in Patients with Benign Prostatic Hyperplasia: A Nationwide Population Based Study Using the National Health Insurance Service Database. J Urol. 2019. PMID: 30840545. doi:10.1097/JU.0000000000000209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。